Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Kartos Therapeutics, Inc.
Scientific Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)